The Center for Regulatory Effectiveness provided testimony to the FDA in support of advancing effective harm reduction strategies. Specifically, CRE advised the agency to state, as an overarching principle, that the marketing of modifiable risk tobacco products will be permitted when it is reasonably clear that:
1. The new product will not be more harmful than existing products; and
2. There is a reasonable scientific basis indicating the new product has the potential to reduce the risk of adverse health effects from consumption of tobacco products.
CRE’s complete testimony is attached below.